← Human Trials & Peer-Reviewed Studies
Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants
Plain-language guide to NCT07840729: phase 1 randomized trial of Semaglutide, 90 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT07840729
- Phase
- phase 1
- Status
- not yet recruiting
- Start
- 2026-10-20
- Completion (planned or actual)
- 2027-02-28
- Participants
- 90 (estimated)
- Design
- randomized, double-blind, treatment
- Conditions studied
- Valid MeSH Conditiongs
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
This registered phase 1 trial tested Semaglutide.
Use these resources to provide understandable information about this study to patients, families, and health care providers:.
It had eight arms (groups): JMT206 injection group 2 (experimental), JMT206 injection group 3 (experimental), JMT206 injection + Semaglutide group 1 (experimental), JMT206 injection + Semaglutide group 2 (experimental) and JMT206 injection + Semaglutide group 3 (experimental).
The registry classes the interventions as combination product and drug.
Who Took Part
Enrollment: 90 planned participants were the target.
It was open to people of any sex aged from 18 years up to 65 years.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: Age 18\~65 (including threshold values), male or female participants;. BMI ≥ 30 kg/m²;. Voluntarily sign the informed consent form before the trial..
The full record lists 4 inclusion and 0 exclusion criteria.
How the Study Was Run
Design: randomized, parallel-group and double-blind.
The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.
The Semaglutide group and the comparison group ran side by side rather than switching.
Neither the participants nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.
Those kept unaware of assignments: participant and care provider.
It started in 2026-10-20 with completion listed for 2027-02-28.
It ran at 1 site in China.
Its stated primary purpose is treatment.
What Was Measured
The main thing measured (primary outcome): Incidence of Adverse Events (AE) assessed by CTCAE v6.0 (time frame: Baseline through week 19).
What This Means in Plain Language
Put simply, this is a phase 1, randomized trial of Semaglutide in 90 people.
Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.